Navigation Links
Orqis(R) Medical's MOMENTUM Trial Abstract Accepted for Late Breaking Clinical Trial Presentation at the American College of Cardiology Annual Meeting

Investigators to Report use of the Cancion(R) System in Patients

Hospitalized with Heart Failure

LAKE FOREST, Calif., Feb. 13 /PRNewswire/ -- Orqis(R) Medical Corporation, a medical products company developing and marketing devices to treat heart failure, announced today that the company's MOMENTUM Trial Abstract was accepted for Late Breaking Clinical Trial presentation at the upcoming annual American College of Cardiology (ACC) meeting in Chicago. The MOMENTUM Trial evaluated the percutaneous Cancion System in patients with acute decompensated heart failure.

Barry Greenberg, M.D., Director, Advanced Heart Failure Treatment Program, University of California San Diego Medical Center, and National Principal Investigator for the MOMENTUM Trial, will present, "Efficacy and Safety of Continuous Aortic Flow Augmentation in Patients Hospitalized with Acute Decompensated Heart Failure: Results of the MOMENTUM Trial," Tuesday, April 1, 2008, from 1:45 pm to 2:00 pm, at the McCormick Place convention center, North Hall B1.

"MOMENTUM is a landmark study examining the hemodynamic and clinical effects of the Cancion System in managing patients hospitalized with heart failure inadequately responsive to medical therapy," stated Dr. Barry Greenberg. Mr. Ken Charhut, President and CEO added, "We are delighted that the MOMENTUM Trial Abstract has been accepted for presentation at the ACC conference and look forward to Dr Greenberg's presentation and dialogue."

About Heart Failure

Over 5 million Americans suffer from heart failure, a condition in which the heart becomes weakened and cannot pump blood efficiently. Heart failure is caused by coronary artery disease, past myocardial infarctions, cardiomyopathy and other underlying cardiovascular disorders, and it is characterized by shortness of breath, functional impairment, and edema. In the U.S., heart failure results in over 1 million hospitalizations annually and is responsible for over $33 billion in direct and indirect costs to the U.S. healthcare system each year.

About Orqis Medical Corporation

Orqis Medical Corporation is a privately held, medical device company seeking to redefine heart failure therapy by developing products that prevent or reverse the underlying disease progression and provide new treatment options to the clinical community to improve patient outcomes and quality of life.

Orqis Medical develops innovative devices that utilize aortic flow augmentation to improve cardiac performance. The percutaneous Cancion System has secured the CE mark and is currently awaiting clearance in the U.S. for extracorporeal support. The implantable Exeleras(R) System is under development.

For more information on Orqis Medical, please visit

Note: Orqis(R), Cancion(R), and Exeleras(R) are registered trademarks of Orqis Medical Corporation.

SOURCE Orqis Medical Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Hooper Holmes Concludes Sale of Medicals Direct
2. Long Term Care Insurance Gains Momentum Thanks to State Promotions, a Leading Brokerage Reports
3. Black AIDS Mobilization Gains Momentum with Congressional Black Caucus Call to Action
4. Eclipsys Announces Strong Market Momentum for Sunrise Pharmacy
5. World Cancer Campaign Builds Momentum Globally with International Initiative to Protect Children From Secondhand Smoke
6. New Heart Pump Shows Promise in Trial
7. Trial to Test Gene Therapy for Angina in Women
8. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
9. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
10. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
11. MDS Pharma Services Wins Award for Management of Global Malaria Trial
Post Your Comments:
(Date:11/27/2015)... ... 2015 , ... Lizzie’s Lice Pickers just announced a special promotion that will ... their purchase of lice treatment product. In addition, customers will receive a complimentary head ... “Finding lice is a sure way to ruin the holidays, so we encourage all ...
(Date:11/27/2015)... ... 27, 2015 , ... Consistent with the Radiology Business ... Better Radiology Marketing Programs meeting will showcase some of the best 2015 ... Caesars Palace in Las Vegas with a pre-conference session on a collaborative approach ...
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping in ... for mental health and wellness consultation, has collaborated with a leading web-based marketplace ... knowledge gap experienced by parents and bring advice from parenting experts within their ...
(Date:11/27/2015)... California (PRWEB) , ... November 27, 2015 , ... Avid ... Joplin Ann Arbor Michigan boxing style concert posters. This is one of Joplin's most ... the Canterbury House at the University of Michigan in Ann Arbor. The According to ...
(Date:11/26/2015)... and Cambridge, ON (PRWEB) , ... November 26, ... ... the availability of a real-time eReferral system for diagnostic imaging in the Waterloo ... X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic medical record ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 2015 ) ... "2016 Future Horizons and Growth Strategies in ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> ) has announced ... Horizons and Growth Strategies in the French ...
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ( ... "Advanced Wound Care Market by Type (Dressings, Therapy Devices, ... (In-Patient Facility, Out-Patient Facility), and Geography - Global Forecast ... --> --> The purpose ... and forecast of the global advanced wound care market. ...
(Date:11/26/2015)... Research and Markets ( ) ... Future Horizons and Growth Strategies in the Italian ... Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report ... --> This new 247-page report ... drug monitoring market, including emerging tests, technologies, instrumentation, ...
Breaking Medicine Technology: